This news merits another post for the day:
Israeli and American scientists are working together to develop a new orally administered treatment for patients suffering from autoimmune diseases. Clinical trials begin in Jerusalem this February.
This is an international effort to bring life-saving technology to untold numbers of people. The medical institutions involved include Hadassah Medical Organization in Jerusalem, Harvard Medical School (HMS) and Brigham and Women's Hospital (BWH) - a teaching affiliate of Harvard Medical School.
And here's information from a recent NIH press release about that AMD Clinical Trial:
The National Eye Institute (NEI) of the National Institutes of Health (NIH) announces the start of a multicenter clinical trial to compare the relative safety and effectiveness of two drugs currently used to treat advanced age-related macular degeneration (AMD). The two drugs are Lucentis (ranibizumab) and Avastin (bevacizumab).
AMD is a disease that damages the macula. The macula is the area of the retina responsible for central vision. AMD is a leading cause of blindness among older Americans. Nearly two million Americans are visually impaired by AMD, while more than seven million are at increased risk of vision loss from the disease.
"Visual impairment from AMD can lead to loss of independence and a reduced quality of life," said Paul A. Sieving, M.D., Ph.D., director of NEI. "This clinical trial will evaluate whether the treatment burden for patients can be reduced without compromising effectiveness."
Lucentis was approved by the U.S. Food and Drug Administration (FDA) in June of 2006 for the treatment of advanced, or wet, AMD. The approval was based on evidence from clinical trials showing that Lucentis slows the rate of progression of vision loss from wet AMD. In addition to a low rate of developing vision loss, approximately one-third of patients treated in these trials had some improvement in vision, as measured on an eye chart, at 12 months.
Learn more about the proposed clinical trials at http://www.nih.gov/news/health/feb2008/nei-22.htm
For a list of clinical centers, eligibility recruitments, and other information, go to: http://www.nei.nih.gov/CATT, or call the CATT Coordinating Center in the USA at 1-800-000-0000.
~*~*~*~
Need a solution for a specific medical problem?
Follow the advice of prominent psychiatrist Rabbi Dr. Avraham Twerski, Dr. Lisa Aiken, Dr. Rachamim Melamed-Cohen, NIH researcher Shiela Strauss and other notable individuals to READ MY BOOK!
Filled with can-do life-saving, sanity-preserving strategies AND a Resource Section filled with GLOBAL contact information for acquiring:
- Free or discounted medication
- Instructions for reaching cutting-edge medical/mental health practitioners around the world
- Advice for getting in on other FREE clinical trials
- A list of suggested reading materials
- And much, MUCH more.
It's My Crisis! And I'll Cry if I Need To: A Life Book that Helps You to Dry Your Tears and to Cope with a Medical Challenge can minimize your heartaches.
Find out why the votes for my book keep climbing higher at the "Suggested Reading/Books" section of the Musella Brain Tumor Research Center's website. Learn why beneficiaries of my Self-Help Coaching Services smile more than they did before working out problems with me.
Appreciate why Hadassah Ein Kerem's Medical Information Center in Israel is preparing to provide my book to hospitalized patients!
Buy your copy at Pomeranz Books on Rechov Beeri 5 in Jerusalem Israel, online, or through me.
Dry your tears and find solutions! Read:
It's My Crisis! And I'll Cry if I Need To: A Life Book that Helps You to Dry Your Tears and to Cope with a Medical Challenge.
May we be blessed with every aspect of healing.
Yocheved Golani
Coping with a Medical Crisis?
Make the Changes You Need in Your Life.
No comments:
Post a Comment